
Spasmodic-torticollis - Pipeline Insight, 2025
Description
DelveInsight’s, “Spasmodic-torticollis - Pipeline Insight, 2025,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Spasmodic-torticollis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Spasmodic-torticollis: Overview
Cervical dystonia, also known as spasmodic torticollis, is a rare neurological disorder that originates in the brain. It is the most common form of focal dystonia in an office setting. Cervical dystonia is characterized by involuntary muscle contractions in the neck that cause abnormal movements and postures of the neck and head. In some cases, these abnormal contractions may be sustained or continuous; in others, they may be present as spasms that can resemble tremor. The severity of cervical dystonia can vary, but the disorder can cause significant pain and discomfort as well as difficulty due to the abnormal postures. It can affect quality of life and activities of daily living including employment. Cervical dystonia typically begins in middle age, and rarely begins in adolescence and young adulthood.
""Spasmodic-torticollis - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Spasmodic-torticollis pipeline landscape is provided which includes the disease overview and Spasmodic-torticollis treatment guidelines. The assessment part of the report embraces, in depth Spasmodic-torticollis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Spasmodic-torticollis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Spasmodic-torticollis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Spasmodic-torticollis Emerging Drugs
Further product details are provided in the report……..
Spasmodic-torticollis: Therapeutic Assessment
This segment of the report provides insights about the different Spasmodic-torticollis drugs segregated based on following parameters that define the scope of the report, such as:
Spasmodic-torticollis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Spasmodic-torticollis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Spasmodic-torticollis drugs.
Spasmodic-torticollis Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Spasmodic-torticollis: Overview
Cervical dystonia, also known as spasmodic torticollis, is a rare neurological disorder that originates in the brain. It is the most common form of focal dystonia in an office setting. Cervical dystonia is characterized by involuntary muscle contractions in the neck that cause abnormal movements and postures of the neck and head. In some cases, these abnormal contractions may be sustained or continuous; in others, they may be present as spasms that can resemble tremor. The severity of cervical dystonia can vary, but the disorder can cause significant pain and discomfort as well as difficulty due to the abnormal postures. It can affect quality of life and activities of daily living including employment. Cervical dystonia typically begins in middle age, and rarely begins in adolescence and young adulthood.
""Spasmodic-torticollis - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Spasmodic-torticollis pipeline landscape is provided which includes the disease overview and Spasmodic-torticollis treatment guidelines. The assessment part of the report embraces, in depth Spasmodic-torticollis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Spasmodic-torticollis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Spasmodic-torticollis R&D. The therapies under development are focused on novel approaches to treat/improve Spasmodic-torticollis.
This segment of the Spasmodic-torticollis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Spasmodic-torticollis Emerging Drugs
- Daxibotulinumtoxin A: Revance Therapeutics
- ABP-450: AEON Biopharma
Further product details are provided in the report……..
Spasmodic-torticollis: Therapeutic Assessment
This segment of the report provides insights about the different Spasmodic-torticollis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Spasmodic-torticollis
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Spasmodic-torticollis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Spasmodic-torticollis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Spasmodic-torticollis drugs.
Spasmodic-torticollis Report Insights
- Spasmodic-torticollis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Spasmodic-torticollis drugs?
- How many Spasmodic-torticollis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Spasmodic-torticollis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Spasmodic-torticollis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Spasmodic-torticollis and their status?
- What are the key designations that have been granted to the emerging drugs?
- Revance Therapeutics
- Medytox
- Addex Pharmaceuticals
- AEON Biopharma
- Daxibotulinumtoxin A
- Meditoxin
- Dipraglurant
- ABP-450
Table of Contents
40 Pages
- Introduction
- Executive Summary
- Spasmodic-torticollis: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Spasmodic-torticollis – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Daxibotulinumtoxin A: Revance Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Dipraglurant: Addex Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Spasmodic-torticollis Key Companies
- Spasmodic-torticollis Key Products
- Spasmodic-torticollis- Unmet Needs
- Spasmodic-torticollis- Market Drivers and Barriers
- Spasmodic-torticollis- Future Perspectives and Conclusion
- Spasmodic-torticollis Analyst Views
- Spasmodic-torticollis Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.